R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more
Market Cap & Net Worth: R&G PharmaStudies Co. Ltd. A (301333)
R&G PharmaStudies Co. Ltd. A (SHE:301333) has a market capitalization of $850.21 Million (CN¥6.24 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #13429 globally and #3473 in its home market, demonstrating a -2.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying R&G PharmaStudies Co. Ltd. A's stock price CN¥64.59 by its total outstanding shares 96581256 (96.58 Million).
R&G PharmaStudies Co. Ltd. A Market Cap History: 2022 to 2026
R&G PharmaStudies Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $670.32 Million to $850.21 Million (4.19% CAGR).
R&G PharmaStudies Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how R&G PharmaStudies Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.88x
R&G PharmaStudies Co. Ltd. A's market cap is 0.88 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.69x
R&G PharmaStudies Co. Ltd. A's market cap is 4.69 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $670.32 Million | $637.52 Million | $113.45 Million | 1.05x | 5.91x |
| 2023 | $843.92 Million | $721.37 Million | $162.53 Million | 1.17x | 5.19x |
| 2024 | $658.03 Million | $744.00 Million | $140.22 Million | 0.88x | 4.69x |
Competitor Companies of 301333 by Market Capitalization
Companies near R&G PharmaStudies Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to R&G PharmaStudies Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
R&G PharmaStudies Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, R&G PharmaStudies Co. Ltd. A's market cap moved from $670.32 Million to $ 850.21 Million, with a yearly change of 4.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥850.21 Million | +8.46% |
| 2025 | CN¥783.87 Million | +19.12% |
| 2024 | CN¥658.03 Million | -22.03% |
| 2023 | CN¥843.92 Million | +25.90% |
| 2022 | CN¥670.32 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of R&G PharmaStudies Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $850.21 Million USD |
| MoneyControl | $850.21 Million USD |
| MarketWatch | $850.21 Million USD |
| marketcap.company | $850.21 Million USD |
| Reuters | $850.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.